Cytolytic cells induce HMGB1 release from melanoma cell lines

Journal of Leukocyte Biology

Volumn 81, Issue 1, 2007, Pages 75-83

  Ito, Norimasa ^a   DeMarco, Richard A ^a   Mailliard, Robbie B ^a   Han, Jie ^a   Rabinowich, Hannah ^a   Kalinski, Pawel ^a   Stolz, Donna Beer ^a   Zeh III, Herbert J ^a   Lotze, Michael T ^a,b  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

Death receptor; Granzyme; Lymphocytes; Necrosis

Indexed keywords

ALANINE; ASPARAGINE; BENZYL DERIVATIVE; CARBONYL DERIVATIVE; CASPASE INHIBITOR; GLYCOPROTEIN GP 100; GRANZYME B; HIGH MOBILITY GROUP B1 PROTEIN; HLA A2 ANTIGEN; INTERLEUKIN 12; KETONE DERIVATIVE; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; VALINE;

ARTICLE; CELL CULTURE; CELL DEATH; CELL NUCLEUS; CONTROLLED STUDY; CYTOLYSIS; CYTOSOL; CYTOTOXICITY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; INCUBATION TIME; LYMPHOKINE ACTIVATED KILLER CELL; MELANOMA CELL; MICROENVIRONMENT; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN LOCALIZATION; SKIN NECROSIS; T LYMPHOCYTE;

ACTIVE TRANSPORT, CELL NUCLEUS; AMINO ACID CHLOROMETHYL KETONES; CELL DEATH; CELL LINE, TUMOR; CELL NUCLEUS; CELLS, CULTURED; CYTOTOXICITY TESTS, IMMUNOLOGIC; FLOW CYTOMETRY; GRANZYMES; HMGB1 PROTEIN; HUMANS; KILLER CELLS, LYMPHOKINE-ACTIVATED; MELANOMA; T-LYMPHOCYTES; TNF-RELATED APOPTOSIS-INDUCING LIGAND;

EID: 33845905487     PISSN: 07415400     EISSN: None     Source Type: Journal    
DOI: 10.1189/jlb.0306169     Document Type: Article

References (26)

1. Bustin, M. (2002) At the crossroads of necrosis and apoptosis: signaling to multiple cellular targets by HMGB1. Sci. STKE 2002, PE39.
2. Kim, R. (2005) Recent advances in understanding the cell death pathways activated by anticancer therapy. Cancer 103, 1551-1560.
3. Lotze, M. T., Tracey, K. J. (2005) High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal. Nat. Rev. Immunol. 5, 331-342.
4. Zeh III, H. J., Lotze, M. T. (2005) Addicted to death: invasive cancer and the immune response to unscheduled cell death. J. Immunother. 28, 1-9.
5. Rovere-Querini, P., Capobianco, A., Scaffidi, P., Valentinis, B., Catalanotti, F., Giazzon, M., Dumitriu, I. E., Muller, S., Iannacone, M., Traversari, C., Bianchi, M. E., Manfredi, A. A. (2004) HMGB1 is an endogenous immune adjuvant released by necrotic cells. EMBO Rep. 5, 825-830.
6. Ameisen, J. C. (2002) On the origin, evolution, and nature of programmed cell death: a timeline of four billion years. Cell Death Differ. 9, 367-393.
7. Lotze, M. T., DeMarco, R. A. (2004) Cancer: cell death without dignity. Discovery Medicine 4, 457-465.
8. Albert, M. L. (2004) Death-defying immunity: do apoptotic cells influence antigen processing and presentation? Nat. Rev. Immunol. 4, 223-231.
9. Dumitriu, I. E., Baruah, P., Valentinis, B., Voll, R. E., Herrmann, M., Nawroth, P. P., Arnold, B., Bianchi, M. E., Manfredi, A. A., Rovere-Querini, P. (2005) Release of high mobility group box 1 by dendritic cells controls T cell activation via the receptor for advanced glycation end products. J. Immunol. 174, 7506-7515.
10. LeBlanc, H., Lawrence, D., Varfolomeev, E., Totpal, K., Morlan, J., Schow, P., Fong, S., Schwall, R., Sinicropi, D., Ashkenazi, A. (2002) Tumor-cell resistance to death receptor-induced apoptosis through mutational inactivation of the proapoptotic Bcl-2 homolog Bax. Nat. Med. 8, 274-281.
11. Winikoff, S. E., Zeh, H. J., DeMarco, R. A., Lotze, M. T. (2005) Cytolytic assays. In Measuring Immunity (M. T. Lotze, A. W. Thomson, eds.), London, UK, Lippincott, 343-349.
12. Mailliard, R. B., Wankowicz-Kalinska, A., Cai, Q., Wesa, A., Hilkens, C. M., Kapsenberg, M. L., Kirkwood, J. M., Storkus, W. J., Kalinski, P. (2004) α-Type-1 polarized dendritic cells: a novel immunization tool with optimized CTL-inducing activity. Cancer Res. 64, 5934-5937.
13. Han, J., Goldstein, L. A., Gastman, B. R., Froelich, C. J., Yin, X. M., Rabinowich, H. (2004) Degradation of Mcl-1 by granzyme B: implications for Bim-mediated mitochondrial apoptotic events. J. Biol. Chem. 279, 22020-22029.
14. Fan, Z., Beresford, P. J., Zhang, D., Lieberman, J. (2002) HMG2 interacts with the nucleosome assembly protein SET and is a target of the cytotoxic T-lymphocyte protease granzyme A. Mol. Cell. Biol. 22, 2810-2820.
15. Lieberman, J., Fan, Z. (2003) Nuclear war: the granzyme A-bomb. Curr. Opin. Immunol. 15, 553-559.
16. Qin, S., Wang, H., Yuan, R., Li, H., Ochani, M., Ochani, K., Rosas-Ballina, M., Czura, C. J., Huston, J. M., Miller, E., Lin, X., Sherry, B., Kumar, A., Larosa, G., Newman, W., Tracey, K. J., Yang, H. (2006) Role of HMGB1 in apoptosis-mediated sepsis lethality. J. Exp. Med. 203, 1637-1642.
17. Huang, B., Zhao, J., Li, H., He, K. L., Chen, Y., Chen, S. H., Mayer, L., Unkeless, J. C., Xiong, H. (2005) Toll-like receptors on tumor cells facilitate evasion of immune surveillance. Cancer Res. 65, 5009-5014.
18. Kuniyasu, H., Yano, S., Sasaki, T., Sasahira, T., Sone, S., Ohmori, H. (2005) Colon cancer cell-derived high mobility group 1/amphoterin induces growth inhibition and apoptosis in macrophages. Am. J. Pathol. 166, 751-760.
19. Ishiguro, H., Nakaigawa, N., Miyoshi, Y., Fujinami, K., Kubota, Y., Uemura, H. (2005) Receptor for advanced glycation end products (RAGE) and its ligand, amphoterin are overexpressed and associated with prostate cancer development. Prostate 64, 92-100.
20. Lotze, M. T., DeMarco, R. A. (2003) Dealing with death: HMGB1 as a novel target for cancer therapy. Curr. Opin. Investig. Drugs 4, 1405-1409.
21. Ulloa, L., Ochani, M., Yang, H., Tanovic, M., Halperin, D., Yang, R., Czura, C. J., Fink, M. P., Tracey, K. J. (2002) Ethyl pyruvate prevents lethality in mice with established lethal sepsis and systemic inflammation. Proc. Natl. Acad. Sci. USA 99, 12351-12356.
22. Pasheva, E. A., Pashev, I. G., Favre, A. (1998) Preferential binding of high mobility group 1 protein to UV-damaged DNA. Role of the COOH-terminal domain. J. Biol. Chem. 273, 24730-24736.
23. Pil, P. M., Lippard, S. J. (1992) Specific binding of chromosomal protein HMG1 to DNA damaged by the anticancer drug cisplatin. Science 256, 234-237.
24. Wang, H., Bloom, O., Zhang, M., Vishnubhakat, J. M., Ombrellino, M., Che, J., Frazier, A., Yang, H., Ivanova, S., Borovikova, L., Manogue, K. R., Faist, E., Abraham, E., Andersson, J., Andersson, U., Molina, P. E., Abumrad, N. N., Sama, A., Tracey, K. J. (1999) HMG-1 as a late mediator of endotoxin lethality in mice. Science 285, 248-251.
25. Nattermann, J., Du, X., Wei, Y., Shevchenko, D., Beutler, B. (2000) Endotoxin-mimetic effect of antibodies against Toll-like receptor 4. J. Endotoxin Res. 6, 257-264.
26. Yang, H., Ochani, M., Li, J., Qiang, X., Tanovic, M., Harris, H. E., Susarla, S. M., Ulloa, L., Wang, H., DiRaimo, R., Czura, C. J., Wang, H., Roth, J., Warren, H. S., Fink, M. P., Fenton, M. J., Andersson, U., Tracey, K. J. (2004) Reversing established sepsis with antagonists of endogenous high-mobility group box 1. Proc. Natl. Acad. Sci. USA 101, 296-301.